Results 61 to 70 of about 9,467,496 (262)

Topical applications of ozone and ozonated oils as anti-infective agents: an insight into the patent claims

open access: yes, 2009
Orthodox medicine has been very active in the field of topical anti-infective agents and current chemotherapy has procured valid antibiotics, antivirals, vaccines, antibodies, and antiparasitic drugs to be parenterally and/or topically used.
Bocci V.   +5 more
core   +1 more source

Therapeutic Efficacy of Clindamycin Gel as an Adjunct to Scaling and Root Planing Therapy in Chronic Periodontal Disease

open access: yesActa Clinica Croatica, 2015
Clindamycin, a lincosamide antibiotic, has been under-recognized as an antimicrobial agent for use in dentistry. The aim of the present work was to evaluate clinical efficacy of 2% clindamycin gel in addition to the basic mechanical periodontal therapy ...
Ana Pejčić   +5 more
doaj  

Comprehensive Characterization of 98 Chinese Cases of Genetic Creutzfeldt‐Jakob Disease With T188K Mutation

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To characterize the demographic, clinical, and laboratory features of the Chinese patients of genetic Creutzfeldt‐Jakob disease with T188K variant (T188K‐gCJD), the most common subtype of genetic prion diseases (gPrDs) in China. Methods In this nationwide retrospective study, data from 98 genetically confirmed T188K‐gCJD patients ...
Chun‐Jie Li   +11 more
wiley   +1 more source

Hybrid compounds as anti-infective agents [PDF]

open access: yes, 2017
Hybrid drugs are multi-target chimeric chemicals combining two or more drugs or pharmacophores covalently linked in a single molecule. In the field of anti-infective agents, they have been proposed as a possible solution to drug resistance issues ...
Sbaraglini, Maria Laura, Talevi, Alan
core   +1 more source

Disease Course After Anti‐CD20 Discontinuation in Secondary Progressive Multiple Sclerosis—A Multicenter Long‐Term Longitudinal Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Ferdinand Otto   +12 more
wiley   +1 more source

The effect of mouthrinses against oral microorganisms Ação dos enxaguatórios bucais contra microrganismos bucais

open access: yesBrazilian Oral Research, 2007
This paper reviews the benefits of the use of antimicrobial mouthrinses for controlling dental biofilm. It is currently known that the human oral cavity is inhabited by approximately 600 to 700 different species of microorganisms, including bacteria ...
José Roberto Cortelli   +1 more
doaj   +1 more source

Recent Advances in Surface Nanoengineering for Biofilm Prevention and Control. Part II: Active, Combined Active and Passive, and Smart Bacteria-Responsive Antibiofilm Nanocoatings

open access: yesNanomaterials, 2020
The second part of our review describing new achievements in the field of biofilm prevention and control, begins with a discussion of the active antibiofilm nanocoatings.
Paul Cătălin Balaure   +1 more
doaj   +1 more source

Anti‐CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non‐Active Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine whether discontinuing anti‐CD20 therapy in people with relapsing‐onset MS aged over 50 is associated with an increased risk of relapse, inflammatory activity, confirmed disability accrual, and serious infection compared with continuing therapy.
Alexia Moukhine   +40 more
wiley   +1 more source

Isolation And Characterization Of Marine Actinomycetes For Anti-Infective Activity Towards Pseudomonas aeruginosa PA14 [PDF]

open access: yes, 2018
Marine environment serve as reservoir of vast useful secondary metabolites and at the same time, new anti-infective agents are required to combat antibiotic resistant pathogenic bacteria.Therefore, this research was carried out to screen for anti ...
Kamal, Siti Nur Fatin Ahmad
core   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Home - About - Disclaimer - Privacy